Acute Myeloid Leukemia Research Today is a free monthly online journal that collates and summarizes the latest research about Acute Myeloid Leukemia, including details on aml, symptoms, treatment, information.

Volume 2 (2005), Issue 11 (November)

1. Negative regulation of p53 by nucleophosmin antagonizes stress-induced apoptosis in human normal and malignant hematopoietic cells.
   Leuk Res, 29(12): 1415-23. [Abstract] [Full-text]
2. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.
   Blood, 106(10): 3658-65. [Abstract] [Full-text]
3. PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism.
   Blood, 106(10): 3584-93. [Abstract] [Full-text]
4. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype.
   Blood, 106(10): 3618-20. [Abstract] [Full-text]
5. Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate.
   Blood, 106(12): 3958-61. [Abstract] [Full-text]
6. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.
   Blood, 106(12): 3733-9. [Abstract] [Full-text]
7. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.
   Leukemia, 19(12): 2030-42. [Abstract] [Full-text]
8. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT).
   Leukemia, 19(12): 2304-12. [Abstract] [Full-text]
9. Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report.
   Leukemia, 19(12): 2072-81. [Abstract] [Full-text]
10. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit--multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group.
    Leukemia, 19(12): 2082-9. [Abstract] [Full-text]
11. Circulating endothelial cells in patients with acute myeloid leukemia.
    Eur J Haematol, 75(6): 492-7. [Abstract] [Full-text]
12. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
    Eur J Haematol, 75(6): 485-91. [Abstract] [Full-text]
13. Expression of poliovirus receptor-related proteins PRR1 and PRR2 in acute myeloid leukemia: first report of surface marker analysis, contribution to diagnosis, prognosis and implications for future therapeutical strategies.
    Eur J Haematol, 75(6): 477-84. [Abstract] [Full-text]
14. Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients.
    Eur J Haematol, 75(6): 468-76. [Abstract] [Full-text]

© 2004-2008 Acute Myeloid Leukemia Research Today. All Rights Reserved.